Skip to main content
Industry News
Medicago, GSK report on plant-derived COVID-19 vaccine

Interim results from a midstage trial for the plant-derived coronavirus vaccine developed by Medicago and being tested with GlaxoSmithKline's pandemic adjuvant showed neutralizing antibody responses were higher tenfold after two doses in vaccinated participants versus recovering COVID-19 patients, both in adults age 18 to 64 and the elderly, those age 65 and older.

Full Story: